Preclinical evaluation of AAV2 anti-VEGF gene therapy using scFv for choroidal neovascularization.

Mol Ther Adv · 2026 · PMC13263680 · PMID 42292913

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Notably, a clear trend toward recovery was observed by 13 weeks post-injection ( Table S5 and S6 ).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.